Anti-TNFalpha polyclonal antibody (Verigen)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti-TNFalpha polyclonal antibody (Verigen)
Drug Alias NamePASSTNF-alpha
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsCrohn DiseaseArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGenzyme Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesItalchimici SpaGenzyme Corp
Active IndicationsN/A
Inactive IndicationsCrohn DiseaseArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksN/A